Why It's Moving

Palantir CEO Warns US-China AI Race Will Have One Winner, Urges West To Keep Up
Rocket Lab, AST SpaceMobile, Virgin Galactic Shares Are Rising After Hours: What's Going On?
Petco Stock Drops After Q1 Revenues Miss: Details
Rocket Lab, AST SpaceMobile, Virgin Galactic Shares Are Rising After Hours: What's Going On?
Petco Stock Drops After Q1 Revenues Miss: Details
Vail Resorts Stock Slides On Q3 Earnings, Company Targets $100 Million In Annualized Cost Efficiencies
Microsoft Hits Record High Amid Strong Tech Sector Momentum: What's Going On?

Why It's Moving Recent News

Samsara Stock Slips Despite Better-Than-Expected Q1 Report
ReplaceRemoveHere's a look at the first-quarter earnings report from Samsara.
Lululemon Q1 Earnings: Revenue Beat, EPS In Line, Shares Tumble On Weaker Earnings Forecast
Lululemon Athletica Inc (NASDAQ:LULU) reported first-quarter financial results Thursday after the market close. Here's a look at the key details from the quarter.
DocuSign Stock Plummets After Q1 Earnings Report: Details
Here's a look at the first-quarter earnings report from DocuSign.
Costco Stock Falls Nearly 4% After May Sales Report Despite Solid Growth
Costco Wholesale Corp. (NASDAQ: COST) shares are trading lower Thursday after the company released its May sales report.
Why Analyst Sees Attractive Valuation For Calvin Klein Parent PVH Despite 'Noisy' Q1
PVH shares are down after cutting FY25 guidance and issuing lower Q2 EPS guidance. Revenue beat estimates in Q1 earnings report.
Palantir Stock Falls As GOP Lawmakers Push Back On Government Surveillance Deal
Palantir Technologies Inc. (NASDAQ: PLTR) shares are trading lower Thursday after backlash from Republican lawmakers over the company's expanding role in U.S. government data operations.
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.
The Trade Desk Stock Drops As Advertisers Shift To Amazon
The Trade Desk Inc. (NASDAQ: TTD) shares are trading lower Thursday after an Adweek report revealed major advertisers are pulling ad dollars from its platform and moving them to Amazon's.
Eyenovia (EYEN) Stock Explodes Following Amended Loan Agreement Terms: What's Going On?
Eyenovia amended its loan with Avenue Capital, changing stock conversion option terms. New rules cap lender ownership and protect rights during major corporate fundamental transactions.
Planet Labs (PL) Shares Surge Over 50% Following Q1 Beat: What's Going On?
Planet Labs stock soared on strong Q1 results and raised fiscal 2026 revenue guidance. Revenue beat estimates; loss narrowed; company saw its first positive free cash flow.
What's Going On With ZJK Stock Thursday?
ZJK announced it will ramp up the production of AI hardware and critical parts to support Nvidia's B40 Project.
ChargePoint (CHPT) Stock Plunges After Disappointing Q1 Revenue And Weak Outlook
ChargePoint shares plunged after Q1 earnings missed expectations, showing declining hardware sales. Revenue fell short, and a weak Q2 forecast overshadowed improved margins and partnerships.
Tissue Titans Unite: Suzano, Kimberly-Clark Form $3.4 Billion Global JV
Suzano S.A. and Kimberly-Clark Corporation announced a $3.4 billion joint venture to create an international tissue company.
IperionX Rockets 23% After Securing $99M Defense Contract For Domestic Titanium
IperionX shares jumped after landing a $99 million U.S. Department of Defense contract for domestically produced titanium.
Toro Lowers Full-Year Outlook As Residential Sales Slump, Costs Weigh on Margins
Toro Q2 sales down 2% Y/Y to $1.32B, missing consensus of $1.35B. Residential segment sales fell 11.4%, segment earnings down to $16.1M from $36.1M. Professional segment sales up 0.8%, segment earnings up to $202.1M from $190.7M. Adjusted EPS of $1.42 (+1% Y/Y), beating consensus of $1.40. Toro lowers FY25 adjusted EPS guidance to $4.15-$4.30, sees net sales growth of flat to -3%. TTC shares down 3.14% at $73.19. Invesco Water Resources ETF (PHO) and Neuberger Berman Small-Mid Cap ETF (NBSM) provide exposure to the stock.
MongoDB Stock Is Moving Higher Thursday: What's Going On?
MongoDB reported better-than-expected first-quarter earnings on Wednesday after the market closed.

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved